Biotech Dodo’s Post

From Loop to the Lab: Chicago is Well-Positioned for Growth Despite Market Challenges The latest EY Beyond Borders report highlights a stark contrast in the biotech industry. While scientific innovation is thriving, with advancements in cell therapies, gene editing, mRNA technology, and novel drug modalities, many biotechs face financial challenges due to a pullback in investor support. Despite these obstacles, Chicago and Illinois are well-positioned to support the industry's growth. The region boasts a highly educated workforce, world-class research institutions, and growing lab infrastructure. Compared to crowded hubs like Boston and the Bay Area, Chicago offers more affordable lab space and access to diverse talent across scientific disciplines. Read more: https://bit.ly/3RciiP6 #biotech #innovation #Chicago #LifeSciences #biotechfinance #startups #research #CellTherapy #GeneEditing #mRNA

The EY Beyond Borders report highlights a dichotomy in the biotech industry, with groundbreaking scientific advancements contrasting against a challenging financial landscape. Funding has declined, IPOs have plummeted, and a significant portion of companies have limited cash reserves. However, the Chicago area and Illinois are uniquely positioned to support the biotech industry during this challenging period

🦤 Psssst…this week’s edition is filled with intrigue: from high-level exits to secret funding deals. It’s all hush-hush for now, but we’re here to lift the lid👇 👣 BenevolentAI CEO steps down as founders make a comeback (Phil Taylor) 🤫 Secretive Treeline Biosciences discloses $421M financing in filing (Nick Paul Taylor) 👻 Another Roche MAGE-A4 trial withdrawn (Liam Casey) 💰Ontario invests $146M in hopes of becoming life sciences hub (Dr. Sushama Chaphalkar) 🔬Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease (Kyle LaHucik, Andrew Dunn) Tune into… 🎧 Tips for Effective Communication in Biotech with Carolyn Scofield, MPS 🎧 Replacing Cells, Restoring Sight with Brian Culley 🎧 The future of gene therapy with Michael Parini Apply to… 📎 Upstream Bioprocess Lead, NanoSyrinx 📎 Senior Scientist in Bio-Physics, Domainex 📎 Scientist II/III Process Development, Oxford Biomedica Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #19 out now: https://lnkd.in/ewqdH36A #biotechdodo #biotech #pharma #digitalhealth #healthtech

Good morning, intrepid readers. As usual, I come bearing biotech news…🦤 This week, Harvard’s whiz-kids unveil a new RNA synthesis method, Flagship Pioneering secures a cosmic $3.6bn raise, while Interius embarks on a Phase I trial in Australia for CAR-T therapy, and a new microbiome gene editing technique comes under the microscope. Finally, investors are back on deck after the funding slump – but is all as it seems? This week’s biotech roundup includes…👇 🧬 Harvard scientist’s enzymatic RNA synthesis tech (Genetic Engineering & Biotechnology News) 💉 Moderna’s Biotech investor raises $3.6bn for new ventures (Oliver Barnes) 🇦🇺 Interius starts Phase I trial of in vivo CAR-T therapy (Tristan Cesar Mañalac) 🐭 Eligo Bioscience achieves first in vivo microbiome base editing (Karen O'Hanlon Cohrt, PhD) 💸 Funding for biotech startups had its best quarter in two years (Kyle LaHucik Tune into… 🎧 Josh Mandel-Brehm - CEO, CAMP4 Therapeutics (First in Human by Vial and Amy Del Medico) 🎧 Engineering Therapeutic Antibodies (Two Scientists Walk Into a Bar by @Maria Wilson) with Yan Wu, and Paul Carter from Genentech Apply to… 📎 Biostatistician, Medpace 📎 Trainee Patent Attorney, Carpmaels & Ransford Boldly explore the latest biotech news with Biotech Dodo’s weekly round-up. Issue #05 out now: https://lnkd.in/eWP9-Awu #biotechdodo #biotech #pharma #digitalhealth #healthtech

Gevorg Grigoryan, PhD, our CTO and co-founder, will be speaking at Genetic Engineering & Biotechnology News' State of AI in Drug Discovery 2024 virtual summit on Wednesday, October 30, at 2:00pm ET. In the panel, “From Computational Platforms to Protein Therapeutics,” Gevorg will explore how #AI-driven platforms are accelerating the design of novel and more effective therapeutics. Moderators Fay Lin, PhD and Kevin Davies, PhD from Genetic Engineering & Biotechnology News will lead the conversation as Gevorg joins Ava Amini from Microsoft and Karen Akinsanya from Schrödinger to discuss AI’s role in transforming drug discovery. Curious to see where AI is taking drug development? https://lnkd.in/eP2Jt3yU #ProgrammingBiology | #GenerativeAI

Latest DON Therapeutics news Artificial intelligence is transforming the biotech industry, boosting drug discovery and development. Some interesting recent developments: - Drug discovery: AI models test billions of connections in a few days (it used to take months and years), identifying promising candidates for further research; - Precision medicine: Machine learning algorithms analyze genetic data to develop personalized treatment plans, improving patient outcomes; - Clinical trials: AI optimizes patient recruitment and trial design, potentially reducing the time and cost of bringing new drugs to market. - Gene editing: AI improves CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology, increasing its accuracy and reducing off-target effects. The union of AI and biotechnology is creating unprecedented opportunities to innovate and improve healthcare. Join the biotech revolution and shape a better tomorrow with DON Therapeutics. More about us on our website https://lnkd.in/eKs-9g9e We are always looking for new possibilities in healthcare. If you are a decision-maker, submit your opportunity via the link: https://lnkd.in/dJfhwVvv   #Biotech #BiotechInnovation #LifeSciences

🔬 Rethinking manufacturing and embracing decentralization can bring therapies closer to patients. In the second of a five-part series – co-authored by Jason C. Foster, Molly Borchardt at Precision AQ, Philip Cyr at Precision AQ, and Erin Lopata at Precision AQ – published on CGTLive, the focus turns to how decentralized manufacturing could transform access to cell and gene therapies. Centralized production has long been the default for CGT manufacturing, but it’s proving inadequate for personalized, time-sensitive treatments. Patients face extended vein-to-vein times, logistical hurdles and high costs that limit access to these life-saving therapies. Decentralized manufacturing offers an alternative. Shifting production closer to treatment centers could reduce delays, cut transportation costs, and accelerate access to critical treatments. Read the second part in the CGTLive series exploring how manufacturing innovation can break down barriers to patient access ⬇️ https://lnkd.in/ekPN4Yyg #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

The biotech industry is going through some interesting times. While recent restructuring efforts have led to notable layoffs across the sector—highlighting the dynamic and often unpredictable nature of this industry—it’s also a period of incredible innovation. Biotech startups are thriving, securing substantial funding throughout 2024 and heading into 2025. This surge in investment is fueling advancements in gene therapy, personalized medicine, and other cutting-edge areas. Despite the challenges, the resilience and creativity within the biotech community continue to drive progress! #Biotech #LifeSciences #Innovation #Healthcare

🤝 🧬 🔬 There is currently a lot of discussion about how #Europe can keep its industry competitive, especially in #biotech where overcoming the translation gap of innovative #science into impactful products is still challenging, as also highlighted in the recent COMPET Council Conclusions of May 24th. Today, Bayer announced a unique partnership to bridge this gap. The aim of the joint project is to bring groundbreaking technologies to patients more quickly while creating a leading biotech ecosystem for #innovative #therapies in Berlin. In order to translate basic #research into benefits for patients faster, Charité - Universitätsmedizin Berlin and Bayer will establish the Berlin Center for Gene and Cell Therapies on the Bayer campus at Berlin Nordhafen. The center will support start-ups bringing their innovative approaches in the area of #cell therapies and #gene therapies into clinical development. At the launch ceremony, Olaf Scholz, Federal Chancellor of Germany highlighted: "With the kick-off of the new translation center, we are also celebrating a unique form of collaboration between #science, #industry and #politics. This institution will become the core of an entire organism of gene and cell-based therapies. To achieve this, we need scientists and entrepreneurs who see both the smallest details in the cell nucleus as well as the big picture: the #medicine of the future that provides answers to the big questions that Rudolf Virchow already posed. Here in Germany we have both: bold research and innovative companies. I wish you every success with this visionary project!" Read more about the project from Prof. Dr. Karl Lauterbach, Federal Minister of Health and Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer | Pharmaceuticals ➡️ https://lnkd.in/gwvc9sQ2 #innovation #competitiveness

The proof is in the paper. More on our latest Nature Biotech paper, and the massive data reveal behind our lead AI drug for idiopathic pulmonary fibrosis for the promising TNIK target from Genetic Engineering & Biotechnology News. ◾ "For those who suspect that AI’s potential is understated, a piece of news has just appeared that will no doubt be taken as confirmation, however partial or contingent it may seem to AI’s doubters." ◾ "The paper, titled “A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models,” describes how scientists at Insilico Medicine and their collaborators leveraged predictive AI technology to bring a drug candidate for idiopathic pulmonary fibrosis (IPF) to the threshold of Phase II development." *Link to full story in comments #ai #genai #drugdiscovery #biotech #techbio #tnik #ipf #clinicaltrials